Neurotechnology Industry Organization Launched to Advance Treatments for Brain and Nervous System Illnesses.
New Global Trade Association to Advocate for the Brain Industry
SAN FRANCISCO San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden -- More than 20 leading pharmaceutical, medical device, and diagnostic companies, along with major academic brain research centers and patient advocacy Patient advocacy refers to speaking on behalf of a patient in order to protect their rights and help them obtain needed information and services. The role of patient advocate is frequently assumed by nurses, social workers, and other healthcare providers. groups, have joined together to form a new trade association called the Neurotechnology Industry Organization The Neurotechnology Industry Organization (NIO) is a San Francisco, California based non-profit trade association that represents a broad spectrum of companies involved in neuroscience, brain research centers, and advocacy groups from around the globe. (NIO NIO
In currencies, this is the abbreviation for the Nicaraguan Coroba Oro.
The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ). Based in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation).
The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] , NIO is a non-profit group created to accelerate the development of treatments and cures for brain and nervous system diseases.
The $110 billion neurotechnology industry includes pharmaceuticals, biologics, cell-based therapeutics and medical devices, as well as diagnostic and surgical equipment for critical unmet needs including: Alzheimer's, addiction, anxiety, depression, epilepsy, hearing loss, insomnia, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, stroke and other brain-related illnesses.
"Despite the clear need and significant market opportunity, neurotechnology companies face a host of issues that stifle innovation, growth and rapid delivery of effective therapies. NIO will provide a collective voice for commercial neuroscience organizations to address these issues," said Zack Lynch, Founder and Executive Director of the newly formed Neurotechnology Industry Organization. "We will kick off our first year with a global awareness campaign highlighting the industry's progress and a public policy tour for members to interact with government officials."
Over 1.5 billion people worldwide and nearly 100 million Americans suffer from a brain or nervous system illness. In addition to untold human suffering, the annual economic burden has reached over $1 trillion worldwide with $300 billion a year in the U.S alone. This burden is accelerating as the population ages and population increases. These factors are creating unprecedented demand for treatments that delay, prevent and cure chronic neurological and psychiatric diseases.
The 500 companies involved in commercial neuroscience face fundamentally different investment requirements, research and development challenges, and regulatory milestones than other life science and healthcare companies. NIO was created to help governments, patients, and the public understand the unique needs of the neurotech industry.
"We are delighted to be a founding member of NIO," said J. Donald deBethizy, Ph.D., President and Chief Executive Officer of Targacept, Inc. "We are pleased that this advocacy group has been formed to address the important issues of our industry."
Founding member organizations span a broad spectrum of drug, device and diagnostic companies from across the world unified by common interests. They include: Acumen Pharmaceuticals (South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , CA), Amarin Corporation (London, England), Brain Resource Company (Sydney, Australia), Ceregene (San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA), Cyberkinetics Neurotechnology Systems Inc. (Boston, MA), NeuroPace (Mountain View, CA), NeuroNova AB (Stockholm, Sweden), Sound Pharmaceuticals (Seattle, WA), Targacept, Inc. (Winston-Salem, NC), and United Therapeutics (Silver Spring, MD); neuroscience research centers including: Allen Institute for Brain Science (Seattle, WA), Blanchette Rockefeller Neurosciences Institute The Neurosciences Institute is a nonprofit research institute that is focused upon "high risk - high payoff" research designed to discover the biological basis of higher-brain function in humans and other animals. (Morgantown, WV), McGovern Institute for Brain Research The McGovern Institute for Brain Research at the Massachusetts Institute of Technology is a research and teaching center, which conducts Integrated Research in neuroscience, molecular neurobiology, cognitive science, computation and related areas. at MIT MIT - Massachusetts Institute of Technology (Cambridge, MA), and the MIND Institute (Albuquerque, NM); patient advocacy groups and research foundations including: Alzheimer's Drug Discovery Foundation (New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY), Epilepsy Therapy Development Project (Reston, VA) and Neurotech Network (Tampa, FL); venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed
5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M  NeuroVentures (Charlottesville, VA) and Technology Partners (Palo Alto, CA); and strategic partner Preston Gates Ellis & Rouvelas Meeds LLP LLP - Lower Layer Protocol (Washington, DC).
About the Neurotechnology Industry Organization
The Neurotechnology Industry Organization (NIO) is a non-profit trade association that represents a broad spectrum of companies involved in neurotechnology (drugs, devices and diagnostics), neuroscience research centers and brain disease advocacy groups across the United States and the world. NIO's mission is to accelerate cures for brain and nervous system diseases by promoting the neurotechnology industry's progress, advocating the industry's position to government officials, and providing business development services to its members. For more information on the Neurotechnology Industry Organization, please visit www.neurotechindustry.org.
About the Neurotechnology Industry
The neurotechnology industry includes companies researching, developing, manufacturing and marketing pharmaceuticals, biologics, cell-based therapeutics and medical devices, as well as diagnostic and surgical equipment for the treatment of brain and nervous system illnesses including: Alzheimer's, addiction, anxiety, depression, epilepsy, hearing loss, insomnia, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, stroke and other brain-related illnesses. In 2005, neurotechnology companies generated over $110 billion in revenue, according to NeuroInsights.